The FDA has issued a safety communication involving potentially dangerous side effects associated with a category of type 2 diabetes drugs known as SGLT2 inhibitors. The agency has warned that use of the drug could lead to ketoacidosis, a serious condition often requiring emergency medical care. Urinary tract infections or... Read more »

A plaintiff who recently filed a lawsuit against Invokana manufacturers Janssen Pharmaceuticals and Johnson & Johnson claims use of the drug to treat type 1 diabetes led to serious kidney damage. The lawsuit further accuses the companies of failing to warn consumers and the medical community about the risk associated with... Read more »

Anthony R. Allen has filed a lawsuit against Johnson & Johnson and Mitsubishi Tanabe Pharm Corp. He claims that the defendants’ prescription medication, Invokana, resulted in serious injuries that could have claimed his life. Allen is an Illinois resident who began using Invokana in December of 2014. The plaintiff’s Invokana... Read more »

A California woman has filed a product lability lawsuit against Janssen Pharmaceuticals and Johnson & Johnson, alleging that the defendants’ product, Invokana, caused serious complications. Jennifer Anzo filed the Invokana lawsuit late in October 2015 in the U.S. District Court for the Eastern District of California. She is demanding compensation... Read more »

Plaintiff Gene Schurman, a resident of Illinois, claims he suffered severe kidney damage after taking the diabetes drug Invokana under the direction of his doctor. He is now suing Janssen Pharmaceuticals, Johnson & Johnson and Mitsubishi Tanabe Pharma Corporation on claims of failure to warn, product liability, design defect, fraud,... Read more »

As concern over risks associated with the type 2 diabetes drug Invokana continues to rise, a new study has shown the same dangers seen with the drug in type 2 diabetes patients may also be present in those with type 1 diabetes. Researchers have found that off-label use of this... Read more »

London-based AstraZeneca failed to obtain FDA approval for a proposed diabetes drug that combines two different medications, saxagliptin and dapagliflozin. In October 2015, the FDA issued a complete response letter to the pharmaceutical giant’s application. The agency requested additional clinical research on the proposed combination drug. AstraZeneca recently released statements... Read more »

Known as a sodium-glucose cotransporter-2, the blockbuster diabetes drug Invokana has been flying off the shelves, launching it to the top of the class of drugs also including Farxiga, Jardiance, Xigduo XR and Glyxambi. The drug presents a new and innovative way to treat the presence of glucose in the... Read more »

Already the subject of increasing controversy in the United States, next generation diabetes drug Invokana is now the target of a newly-filed class action lawsuit in Canada. Filed at the Ontario Superior Court of Justice, the lawsuit alleges that Jannsen’s treatment for Type 2 diabetes poses a serious risk of kidney... Read more »

The U.S. Food and Drug Administration (FDA) has released a new drug safety communication regarding Invokana and Invokamet (canagliflozin). The safety announcement, which was released on September 10, 2015, adds a new warning to the drug’s label and updates the adverse reactions section with regard to the risk of bone... Read more »